share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股SEC公告 ·  09/30 08:03
Moomoo AI 已提取核心信息
On September 30, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific tranche was initiated on August 7, 2024, with the intention to repurchase up to DKK 2.4 billion in B shares by November 4, 2024. Since the last announcement on September 23, 2024, Novo Nordisk has purchased an additional 205,935 B shares at an average price of DKK 835.48, amounting to DKK 172,706,664. This brings the total repurchased under the program to 1,604,058 B shares at an average price of DKK 880.84, totaling DKK 11,161,264,179. The company now holds 13,999,815 B shares as treasury shares, representing 0.3% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.
On September 30, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific tranche was initiated on August 7, 2024, with the intention to repurchase up to DKK 2.4 billion in B shares by November 4, 2024. Since the last announcement on September 23, 2024, Novo Nordisk has purchased an additional 205,935 B shares at an average price of DKK 835.48, amounting to DKK 172,706,664. This brings the total repurchased under the program to 1,604,058 B shares at an average price of DKK 880.84, totaling DKK 11,161,264,179. The company now holds 13,999,815 B shares as treasury shares, representing 0.3% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.
2024年9月30日，全球领先的医疗保健公司诺和诺德报告了其股份回购计划的进展。该计划始于2024年2月6日，旨在在12个月内回购价值高达200亿丹麦克朗的股份。作为这一倡议的一部分，特定 tranche 于2024年8月7日启动，计划在2024年11月4日前回购价值高达24亿丹麦克朗的 b 股。自2024年9月23日的最后一次公告以来，诺和诺德以DKK835.48的平均价格又购买了2059350亿股，金额为DKK172,706,664。这使得在该计划下回购的总股数达到16040580亿股，平均价格为DKK880.84，总计DKK11,161,264,179。公司目前持有139998150亿股作为库存股，占股份资本的0.3%。诺和诺德成立于1923年，总部位于丹麦，致力于对抗严重慢性疾病，在全球约有约69,000名员工。
2024年9月30日，全球领先的医疗保健公司诺和诺德报告了其股份回购计划的进展。该计划始于2024年2月6日，旨在在12个月内回购价值高达200亿丹麦克朗的股份。作为这一倡议的一部分，特定 tranche 于2024年8月7日启动，计划在2024年11月4日前回购价值高达24亿丹麦克朗的 b 股。自2024年9月23日的最后一次公告以来，诺和诺德以DKK835.48的平均价格又购买了2059350亿股，金额为DKK172,706,664。这使得在该计划下回购的总股数达到16040580亿股，平均价格为DKK880.84，总计DKK11,161,264,179。公司目前持有139998150亿股作为库存股，占股份资本的0.3%。诺和诺德成立于1923年，总部位于丹麦，致力于对抗严重慢性疾病，在全球约有约69,000名员工。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息